| Therapeutic | Dupilumab |
| Target | IL4R/CD124 |
| Heavy Chain | EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS |
| Light Chain | DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK |
| 100% seqID Fv Structure | 6wg8 [Fvs: AB], 6wgb [Fvs: AB, CD], 6wgj [Fvs: AB, CD, EF], 6wgk [Fvs: AB, CD, EF, GH], 6wgl [Fvs: AB] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6wgb [Fvs: AB, CD] |
| 100% seqID Structure | 6wgj [Fvs: AB, CD, EF] |
| 100% seqID Structure | 6wgk [Fvs: AB, CD, EF, GH] |
| 100% seqID Structure | 6wgl [Fvs: AB] |
| 100% seqID Structure | 6wg8 [Fvs: AB] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (Aug '24) | Approved |
| Estimated Status (Aug '24) | Active |
| Recorded Developmental Technology | VelocImmune Mouse |
| INN Year Proposed | 2012 |
| INN Year Recommended | 2013 |
| Companies Involved | Aimmune Therapeutics, Regeneron Pharmaceuticals, Sanofi |
| Conditions Approved | Asthma, Atopic dermatitis, Nasal polyps |
| Conditions Active | Chronic obstructive pulmonary disease, Eosinophilic oesophagitis, Grass pollen hypersensitivity, Peanut hypersensitivity, Urticaria |
| Conditions Discontinued | Allergic asthma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
